References
- Finkel SI, Costa e Silva J, Cohen G, Miller S, Sartorius N. Behavioral and psychological signs and symptoms of dementia: a consensus statement on current knowledge and implications for research and treatment. Int. Psychogeriatr. 8 (Suppl. 3), 497–500 (1996).
- Ikeda M, Fukuhara R, Shigenobu K et aL Dementia-associated mental and behavioral disturbances in community dwelling elderly: findings from the first Nakayama study. J. NeuroL Neurosurg. Psychiatry 75, 146–148 (2004).
- Katz IR, Jeste DV, Mintzer JE, Clyde C, Napolitano J, Brecher M. Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial.Clin. Psychiatry60, 107–115 (1999).
- De Deyn PP, Carrasco MM, Deberdt W et aL Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease. Int. J Geriatr. Psychiatry 19, 115–126 (2004).
- Ikeda M, Shigenobu K, Fukuhara R et aL Delusions of Japanese patients with Alzheimer's disease. Int. J Geriatr. Psychiatry 18, 527–532 (2003).
- Shigenobu K, Ikeda M, Fukuhara R et al. Reducing the burden of care for Alzheimer's disease through the amelioration of delusions of theft by drug therapy. Int. J Geriat. Psychiatry 17, 211–217 (2002).
- McKeith IG, Galasko D, Kosaka K et al. Consensus guidelines for the clinical and pathological diagnosis of dementia with Lewy bodies (DLB). Report of the consortium on DLB international workshop. Neurology47, 1113–1124 (1996).
- Samuel W, Caligiuri M, Galasko D et aL Better cognitive and psychopathologic response to donepezil in patients prospectively diagnosed as dementia with Lewy bodies: a preliminary study. Int. J. Geriatr. Psychiatry 15, 794–802 (2000).
- McKeith I, Del Ser T, Spano P et aL Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet356, 2031–2036 (2000).
- Tanabe H, Ikeda M, Komori K. Behavioral symptomatology and care of patients with frontotemporal lobe degeneration: based on the aspects of the phylogenetic and ontogenetic processes. Dement. Geriatr. Cogn. Disord. 10 (Suppl. 1), 50–54 (1999).
- Swartz JR, Miller BL, Lesser IM, Darby AL. Frontotemporal dementia: treatment response to serotonin selective reuptake inhibitors. J Clin. Psychiatry58, 212–216 (1997).
- Ikeda M, Shigenobu K, Fukuhara R et al. Efficacy of fluvoxamine as a treatment for behavioral symptoms in FTLD patients. Dement. Geriatr. Cogn. Disord. 17, 117–121 (2004).
- Moretti R, Torre P, Antonello RM, Cazzato G, Bava A. Frontotemporal dementia: paroxetine as a possible treatment of behavior symptoms. A randomized, controlled, open 14-month study. Eur. NeuroL 49, 13–19 (2003).
- Stekke LF, Hasenbroekx C, Pasquier Frontotemporal dementia: a randomized, controlled trial with trazodone. Dement. Geriatr. Cogn. Disord. 17, 355–359 (2004).